The American Journal of Managed Care2d
FDA Approves Mirdametinib for Neurofibromatosis Type 1 With Plexiform Neurofibromas
Adult and pediatric patients with neurofibromatosis type 1 who have symptomatic plexiform neurofibromas that are not amenable ...
Pharm Exec2d
FDA Approves SpringWorks Therapeutics’ Gomekli for Neurofibromatosis Type 1, Symptomatic Plexiform Neurofibromas
Approval makes Gomekli the first treatment to be approved for both adults and pediatric patients for neurofibromatosis type 1 ...
Cuba Headlines3d
Cuban Woman Holds Solo Protest Outside Havana Hospital for Damir's Health: "This Is Why We Are Where We Are"
A Cuban woman staged a solitary protest outside the "Juan Manuel Márquez" Pediatric Hospital in Havana, demanding medical care for 10-year-old Damir ...
Cuba Headlines6d
Damir's Determined Fight for a Humanitarian Visa Amid Hospital Hurdles
Ten-year-old Damir Ortiz Ramírez, a Cuban child, is battling serious health issues while his family, alongside several activists, tirelessly pursues ...
Managed Healthcare Executive7h
FDA Approves Gomekli, First and Only NF1-PN Treatment for Both Children and Adults
Gomekli is the second ever FDA-approved treatment for rare tumor disease, NF1-PN and the first to be approved for both adult and pediatric patients.
GlobalData on MSN2d
FDA approves Gomekli as first neurofibromatosis drug for adults
The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat ...
UPDATE: SpringWorks Therapeutics Announces FDA Approval of GOMEKLIâ„¢ (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN
GOMEKLI is the first and only medicine approved for both adults and children with NF1-PN –– Approval based on positive data ...